{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363388845512434432.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1200/jco.2014.59.1792"}},{"identifier":{"@type":"URI","@value":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2014.59.1792"}}],"dc:title":[{"@value":"Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec><jats:title>Purpose</jats:title><jats:p> Findings on the association between risk of cardiovascular disease (CVD) and the duration and type of androgen-deprivation therapy (ADT) in men with prostate cancer (PCa) are inconsistent. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> By using data on filled drug prescriptions in Swedish national health care registers, we investigated the risk of CVD in a cohort of 41,362 men with PCa on ADT compared with an age-matched, PCa-free comparison cohort (n = 187,785) by use of multivariable Cox proportional hazards regression models. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> From 2006 to 2012, 10,656 men were on antiandrogens (AA), 26,959 were on gonadotropin-releasing hormone (GnRH) agonists, and 3,747 underwent surgical orchiectomy. CVD risk was increased in men on GnRH agonists compared with the comparison cohort (hazard ratio [HR] of incident CVD, 1.21; 95% CI, 1.18 to 1.25; and orchiectomy: HR, 1.16; 95% CI, 1.08 to 1.25). Men with PCa on AA were at decreased risk (HR of incident CVD, 0.87; 95% CI, 0.82 to 0.91). CVD risk was highest during the first 6 months of ADT in men who experienced two or more cardiovascular events before therapy, with an HR of CVD during the first 6 months of GnRH agonist therapy of 1.91 (95% CI, 1.66 to 2.20), an HR of CVD with AA of 1.60 (95% CI, 1.24 to 2.06), and an HR of CVD with orchiectomy of 1.79 (95% CI, 1.16 to 2.76) versus the comparison cohort. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Our results support that there should be a solid indication for ADT in men with PCa so that benefit outweighs potential harm; this is of particular importance among men with a recent history of CVD. </jats:p></jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383388845512434434","@type":"Researcher","foaf:name":[{"@value":"Sean O'Farrell"}],"jpcoar:affiliationName":[{"@value":"Sean O'Farrell, Hans Garmo, Lars Holmberg, and Mieke Van Hemelrijck, King's College London, School of Medicine; Sean O'Farrell, Guy's and St Thomas' National Health Service Foundation Trust and King's College London's Comprehensive Biomedical Research Centre, London, United Kingdom; Hans Garmo and Lars Holmberg, Regional Cancer Centre, Uppsala Örebro; Lars Holmberg, Uppsala University, Uppsala; Jan Adolfsson and Mieke Van Hemelrijck, Karolinska Institutet, Stockholm; and Pär Stattin, Umeå University,..."}]},{"@id":"https://cir.nii.ac.jp/crid/1383388845512434435","@type":"Researcher","foaf:name":[{"@value":"Hans Garmo"}],"jpcoar:affiliationName":[{"@value":"Sean O'Farrell, Hans Garmo, Lars Holmberg, and Mieke Van Hemelrijck, King's College London, School of Medicine; Sean O'Farrell, Guy's and St Thomas' National Health Service Foundation Trust and King's College London's Comprehensive Biomedical Research Centre, London, United Kingdom; Hans Garmo and Lars Holmberg, Regional Cancer Centre, Uppsala Örebro; Lars Holmberg, Uppsala University, Uppsala; Jan Adolfsson and Mieke Van Hemelrijck, Karolinska Institutet, Stockholm; and Pär Stattin, Umeå University,..."}]},{"@id":"https://cir.nii.ac.jp/crid/1383388845512434432","@type":"Researcher","foaf:name":[{"@value":"Lars Holmberg"}],"jpcoar:affiliationName":[{"@value":"Sean O'Farrell, Hans Garmo, Lars Holmberg, and Mieke Van Hemelrijck, King's College London, School of Medicine; Sean O'Farrell, Guy's and St Thomas' National Health Service Foundation Trust and King's College London's Comprehensive Biomedical Research Centre, London, United Kingdom; Hans Garmo and Lars Holmberg, Regional Cancer Centre, Uppsala Örebro; Lars Holmberg, Uppsala University, Uppsala; Jan Adolfsson and Mieke Van Hemelrijck, Karolinska Institutet, Stockholm; and Pär Stattin, Umeå University,..."}]},{"@id":"https://cir.nii.ac.jp/crid/1383388845512434433","@type":"Researcher","foaf:name":[{"@value":"Jan Adolfsson"}],"jpcoar:affiliationName":[{"@value":"Sean O'Farrell, Hans Garmo, Lars Holmberg, and Mieke Van Hemelrijck, King's College London, School of Medicine; Sean O'Farrell, Guy's and St Thomas' National Health Service Foundation Trust and King's College London's Comprehensive Biomedical Research Centre, London, United Kingdom; Hans Garmo and Lars Holmberg, Regional Cancer Centre, Uppsala Örebro; Lars Holmberg, Uppsala University, Uppsala; Jan Adolfsson and Mieke Van Hemelrijck, Karolinska Institutet, Stockholm; and Pär Stattin, Umeå University,..."}]},{"@id":"https://cir.nii.ac.jp/crid/1383388845512434437","@type":"Researcher","foaf:name":[{"@value":"Pär Stattin"}],"jpcoar:affiliationName":[{"@value":"Sean O'Farrell, Hans Garmo, Lars Holmberg, and Mieke Van Hemelrijck, King's College London, School of Medicine; Sean O'Farrell, Guy's and St Thomas' National Health Service Foundation Trust and King's College London's Comprehensive Biomedical Research Centre, London, United Kingdom; Hans Garmo and Lars Holmberg, Regional Cancer Centre, Uppsala Örebro; Lars Holmberg, Uppsala University, Uppsala; Jan Adolfsson and Mieke Van Hemelrijck, Karolinska Institutet, Stockholm; and Pär Stattin, Umeå University,..."}]},{"@id":"https://cir.nii.ac.jp/crid/1383388845512434436","@type":"Researcher","foaf:name":[{"@value":"Mieke Van Hemelrijck"}],"jpcoar:affiliationName":[{"@value":"Sean O'Farrell, Hans Garmo, Lars Holmberg, and Mieke Van Hemelrijck, King's College London, School of Medicine; Sean O'Farrell, Guy's and St Thomas' National Health Service Foundation Trust and King's College London's Comprehensive Biomedical Research Centre, London, United Kingdom; Hans Garmo and Lars Holmberg, Regional Cancer Centre, Uppsala Örebro; Lars Holmberg, Uppsala University, Uppsala; Jan Adolfsson and Mieke Van Hemelrijck, Karolinska Institutet, Stockholm; and Pär Stattin, Umeå University,..."}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"0732183X"},{"@type":"EISSN","@value":"15277755"}],"prism:publicationName":[{"@value":"Journal of Clinical Oncology"}],"dc:publisher":[{"@value":"American Society of Clinical Oncology (ASCO)"}],"prism:publicationDate":"2015-04-10","prism:volume":"33","prism:number":"11","prism:startingPage":"1243","prism:endingPage":"1251"},"reviewed":"false","url":[{"@id":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2014.59.1792"}],"createdAt":"2015-03-03","modifiedAt":"2022-05-26","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360025430193569664","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Assessment of Cardiovascular Events Caused by New-Generation Androgen Receptor Pathway Inhibitors Used for Prostate Cancer: A Real-World Study in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848658385626496","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865814737797504","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"<scp>Real‑world</scp> survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for <scp>nonmetastatic castration‐resistant</scp> prostate cancer"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1200/jco.2014.59.1792"},{"@type":"CROSSREF","@value":"10.1159/000540864_references_DOI_X5yxWQYIZcF3dCU6I0GgY8fldsY"},{"@type":"CROSSREF","@value":"10.1038/pcan.2015.50_references_DOI_X5yxWQYIZcF3dCU6I0GgY8fldsY"},{"@type":"CROSSREF","@value":"10.1002/cam4.6536_references_DOI_X5yxWQYIZcF3dCU6I0GgY8fldsY"}]}